Heart Failure from Heart Muscle Disease in Childhood: a 5-10 Year Follow-up Study in the UK and Ireland
Overview
Affiliations
Aims: Our original study, the first national prospective study of new-onset heart failure from heart muscle disease in children, showed overall 1-year survival of 82%, and event (death or transplantation)-free survival of 66%. This study aimed to evaluate 5 + year outcomes of this important cohort.
Methods And Results: All centres in the UK and Ireland with 1-year event-free survivors participated ( = 14). Anonymised data based on last hospital attendance and echocardiograms were reviewed. The investigator was blinded to outcome at the time of echo review. Of sixty-nine 1-year event-free survivors, data were obtained on 64, with three lost to follow-up and two moved abroad. There were three deaths at 2.2, 3.3 and 9.0 years after presentation and one transplant, at 5.2 years. Overall/event-free survival was 77%/62% at 5 years and 73%/59% at 10 years, respectively. Overall and event-free survival conditional on 1-year survival was 94% at 5 years, and 89% at 10 years. For the 60 event-free survivors, median (range) follow-up duration was 9.04 (5.0-10.33) years for those still under review ( = 45), or time to discharge 5.25 (0.67-10.0) years ( = 15). Fifty-eight were in New York Heart Association (NYHA) Class 1, and two in Class 2. Forty-one out of sixty had normal echocardiograms at last follow-up. Predictors of better longer-term outcome were the same as for the original 1-year follow-up study, namely, younger age and higher fractional shortening measurement at presentation.
Conclusions: Children who survive the first year following their first presentation with significant heart failure from heart muscle disease have a good longer-term outcome although there remains a small attrition rate.
Ding W, Wang B, Hong J, Lu L, Xiao Y, Shan G J Am Heart Assoc. 2024; 13(19):e029121.
PMID: 39344650 PMC: 11681489. DOI: 10.1161/JAHA.122.029121.
Tamoxifen may contribute to preserve cardiac function in Duchenne muscular dystrophy.
Henzi B, Lava S, Spagnuolo C, Putananickal N, Donner B, Pfluger M Eur J Pediatr. 2024; 183(9):4057-4062.
PMID: 38960907 PMC: 11322393. DOI: 10.1007/s00431-024-05670-9.
Rella V, Parati G, Crotti L Front Pediatr. 2020; 8:139.
PMID: 32318526 PMC: 7146705. DOI: 10.3389/fped.2020.00139.
Lee T, Hsu D, Kantor P, Towbin J, Ware S, Colan S Circ Res. 2017; 121(7):855-873.
PMID: 28912187 PMC: 5657298. DOI: 10.1161/CIRCRESAHA.116.309386.
Andrews R, Fenton M, Dominguez T, Burch M ESC Heart Fail. 2016; 3(2):107-114.
PMID: 27812385 PMC: 5066798. DOI: 10.1002/ehf2.12082.